Spots Global Cancer Trial Database for primary mediastinal large b cell lymphoma
Every month we try and update this database with for primary mediastinal large b cell lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity | NCT04503538 | Large B-cell Ly... Diffuse Large B... Primary Mediast... High-grade B-ce... Follicular Lymp... | Telemedicine vi... | 18 Years - | Wake Forest University Health Sciences | |
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Neoplasms | VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125... | 18 Years - | Vincerx Pharma, Inc. | |
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Neoplasms | VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125... | 18 Years - | Vincerx Pharma, Inc. | |
| Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma | NCT05326243 | Diffuse Large B... Primary Mediast... Large B-cell Ly... Follicular Lymp... Follicular Lymp... | CD19-targeted c... | 14 Years - 70 Years | Pell Bio-Med Technology Co., Ltd. | |
| Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL | NCT04705129 | Primary Mediast... EBV-Positive DL... | Zanubrutinib Tislelizumab | 18 Years - 80 Years | Ruijin Hospital | |
| Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma | NCT05326243 | Diffuse Large B... Primary Mediast... Large B-cell Ly... Follicular Lymp... Follicular Lymp... | CD19-targeted c... | 14 Years - 70 Years | Pell Bio-Med Technology Co., Ltd. | |
| A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL | NCT02423291 | Primary Mediast... | Brentuximab Ved... | 18 Years - | Fondazione Italiana Linfomi - ETS | |
| RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies | NCT04844086 | B-cell Acute Ly... Non-Hodgkin's L... Non-Hodgkin's L... Primary Mediast... Diffuse Large B... Follicular Lymp... Mantle Cell Lym... High-grade B-ce... | RPM CD19-mbIL15... | 20 Years - 75 Years | Eden BioCell Ltd. | |
| Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation | NCT01516567 | Primary Mediast... | Etoposide, Doxo... | 6 Months - 17 Years | Gustave Roussy, Cancer Campus, Grand Paris | |
| Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity | NCT04503538 | Large B-cell Ly... Diffuse Large B... Primary Mediast... High-grade B-ce... Follicular Lymp... | Telemedicine vi... | 18 Years - | Wake Forest University Health Sciences | |
| A Prospective Study: Sintilimab and R-CHOP in PMBCL Treatment | NCT06412068 | Primary Mediast... | Combined anti-P... | 18 Years - 75 Years | Sun Yat-sen University | |
| Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy | NCT05377307 | Diffuse Large B... Large B-cell Ly... Primary Mediast... Follicular Lymp... Follicular Lymp... | Pell's lentivir... | - | Pell Bio-Med Technology Co., Ltd. | |
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Neoplasms | VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125... | 18 Years - | Vincerx Pharma, Inc. | |
| Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma | NCT04545762 | Refractory Non-... Burkitt Lymphom... Mantle Cell Lym... Follicular Lymp... Lymphoplasmacyt... Primary Mediast... Diffuse Large B... Small Lymphocyt... Transformed Lym... | Fludarabine Cyclophosphamid... anti-CD19 CAR-T... | 18 Years - | University of California, San Francisco | |
| Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation | NCT01516567 | Primary Mediast... | Etoposide, Doxo... | 6 Months - 17 Years | Gustave Roussy, Cancer Campus, Grand Paris | |
| 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers | NCT04464200 | Diffuse Large B... Primary Mediast... Transformed Fol... Chronic Lymphoc... Indolent Non-Ho... Marginal Zone L... Waldenstrom Mac... Burkitt's Lymph... Primary CNS Lym... | 19(T2)28z1xx CA... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Neoplasms | VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125... | 18 Years - | Vincerx Pharma, Inc. | |
| ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies | NCT05653271 | B-cell Lymphoma Non Hodgkin Lym... DLBCL Primary Mediast... Marginal Zone L... Follicular Lymp... | Cyclophosphamid... Fludarabine ACE1831 Obinutuzumab | 18 Years - | Acepodia Biotech, Inc. | |
| Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL | NCT04705129 | Primary Mediast... EBV-Positive DL... | Zanubrutinib Tislelizumab | 18 Years - 80 Years | Ruijin Hospital | |
| Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL | NCT04705129 | Primary Mediast... EBV-Positive DL... | Zanubrutinib Tislelizumab | 18 Years - 80 Years | Ruijin Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
